EMA Authorised: Orencia (abatacept) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA authorised Orencia (abatacept) by Bristol-Myers Squibb Pharma EEIG for rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• ORENCIA (ABATACEPT)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 24/06/2024